1.01
price down icon0.98%   -0.01
 
loading

Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten

pulisher
Dec 19, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia

Dec 19, 2024
pulisher
Dec 18, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India

Dec 18, 2024
pulisher
Dec 18, 2024

Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com

Dec 18, 2024
pulisher
Dec 18, 2024

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat

Dec 18, 2024
pulisher
Dec 16, 2024

Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat

Dec 16, 2024
pulisher
Dec 13, 2024

Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com

Dec 13, 2024
pulisher
Nov 29, 2024

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 29, 2024
pulisher
Nov 29, 2024

Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan

Nov 29, 2024
pulisher
Nov 29, 2024

Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail

Nov 29, 2024
pulisher
Nov 29, 2024

Strong week for Cue Biopharma (NASDAQ:CUE) shareholders doesn't alleviate pain of five-year loss - Simply Wall St

Nov 29, 2024
pulisher
Nov 25, 2024

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

Nov 25, 2024
pulisher
Nov 25, 2024

Cue Biopharma CEO to Present Clinical Updates at Piper Sandler Healthcare Conference | CUE Stock News - StockTitan

Nov 25, 2024
pulisher
Nov 25, 2024

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 25, 2024
pulisher
Nov 25, 2024

Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by GSA Capital Partners LLP - Defense World

Nov 25, 2024
pulisher
Nov 17, 2024

Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024
pulisher
Nov 16, 2024

Cue Biopharma’s Nasdaq Compliance Struggle: Risks and Implications for Future Stability - MSN

Nov 16, 2024
pulisher
Nov 15, 2024

Jefferies cuts Cue Biopharma shares target, retains buy rating on potential - Investing.com UK

Nov 15, 2024
pulisher
Nov 15, 2024

Cue Biopharma earnings beat, revenue topped estimates By Investing.com - Investing.com UK

Nov 15, 2024
pulisher
Nov 15, 2024

Cue Biopharma Inc (CUE) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 15, 2024

Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role - MSN

Nov 15, 2024
pulisher
Nov 15, 2024

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times

Nov 15, 2024
pulisher
Nov 14, 2024

Cue Biopharma Reports Increased Revenue Amid Ongoing Losses - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Cue Biopharma Inc (CUE) Q3 2024 Earnings: EPS of $0.17 Beats Est - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Cue Biopharma's Cancer Drug Shows 91% Survival Rate in Phase 1 Trial, Revenue Up 57% | CUE Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Cue Biopharma Announces Strategic Organizational Transition - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Cue Biopharma Strengthens Leadership: J&J Veteran with 15+ Drug Approvals Joins as CDO | CUE Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 12, 2024

Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus reshapes outlook - Investing.com Australia

Nov 12, 2024
pulisher
Nov 12, 2024

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Cue Biopharma to Present Latest Clinical Trial Data at Stifel Healthcare Conference | CUE Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews

Nov 11, 2024
pulisher
Nov 09, 2024

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting - The Manila Times

Nov 09, 2024
pulisher
Nov 08, 2024

Cue Biopharma Presents Positive Updated Data from its Phase - GlobeNewswire

Nov 08, 2024
pulisher
Nov 08, 2024

Cue Biopharma Cancer Drug Trial Soars: 91% Survival Rate, Shatters Expectations | CUE Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 04, 2024

Ballard Power Systems Inc (BLDP-T) QuotePress Release - The Globe and Mail

Nov 04, 2024
pulisher
Oct 26, 2024

Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat

Oct 26, 2024
pulisher
Oct 12, 2024

Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail

Oct 12, 2024
pulisher
Oct 09, 2024

Cue Biopharma authorizes more shares By Investing.com - Investing.com Australia

Oct 09, 2024
pulisher
Oct 09, 2024

Cue Biopharma authorizes more shares - Investing.com India

Oct 09, 2024
pulisher
Oct 09, 2024

There is no doubt that Cue Biopharma Inc (CUE) ticks all the boxes. - SETE News

Oct 09, 2024
pulisher
Oct 09, 2024

Market Watch: Cue Biopharma Inc (CUE)’s Noteworthy Drop, Closing at 1.23 - The Dwinnex

Oct 09, 2024
pulisher
Oct 08, 2024

Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89% - Yahoo Finance

Oct 08, 2024
pulisher
Oct 07, 2024

Technical analysis of Cue Biopharma Inc (CUE) stock chart patterns - US Post News

Oct 07, 2024
pulisher
Oct 05, 2024

Cue Biopharma stock rallies nearly 40% on upcoming presentations - MSN

Oct 05, 2024
pulisher
Oct 05, 2024

Cue Biopharma amends loan agreement, easing cash requirements - Investing.com India

Oct 05, 2024
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Kapitalisierung:     |  Volumen (24h):